Urogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow URGN
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
21.46 | 73.20 | 101.57 | 147.60 | 103.24 | 90.37 | 100.78 | 137.79 | 237.76 | 121.81 |
Receivables |
0.08 | — | — | — | 7.05 | 11.72 | 12.70 | 15.44 | 20.30 | 33.08 |
Inventory |
0.11 | 0.32 | 0.32 | — | 1.96 | 4.83 | 4.33 | 5.67 | 9.23 | 16.46 |
Total current assets |
22.04 | 74.47 | 102.24 | 148.63 | 115.62 | 114.39 | 128.91 | 169.19 | 276.14 | 186.02 |
Property, Plant, Equpment (Net) |
0.74 | 0.81 | 0.95 | 0.98 | 2.05 | 1.97 | 1.30 | 0.69 | 0.66 | 0.64 |
Long-Term Investments |
0.02 | 0.03 | 0.05 | 48.56 | 1.89 | 0.68 | 0.22 | 4.50 | 5.02 | — |
Long-term assets (Other) |
0.27 | 0.27 | 0.37 | 0.49 | 0.29 | 1.53 | 2.96 | 2.26 | 0.77 | 5.34 |
Total non-current assets |
1.02 | 1.08 | 1.32 | 53.75 | 6.39 | 5.36 | 6.71 | 9.13 | 9.58 | 14.43 |
Total Assets |
23.06 | 75.55 | 103.56 | 202.39 | 122.01 | 119.75 | 135.62 | 178.31 | 285.71 | 200.46 |
Accounts Payable |
1.88 | 4.44 | 8.54 | 11.19 | 10.02 | 12.10 | 12.38 | 16.54 | 27.43 | 27.72 |
Accrued Expenses |
0.69 | 1.95 | 4.93 | 6.71 | 9.55 | 6.95 | 8.26 | 10.81 | 10.57 | 13.52 |
Current Revenue (Deferred) |
— | 0.65 | — | — | — | — | — | — | — | — |
Other current liabilities |
0.57 | 2.60 | 9.19 | 1.59 | 1.86 | 3.33 | 3.28 | 3.86 | 7.95 | 5.19 |
Total current liabilities |
3.14 | 7.04 | 13.47 | 19.48 | 21.44 | 22.38 | 23.92 | 31.21 | 45.95 | 46.42 |
Long Term Debt (Total) |
— | — | — | 2.60 | 1.50 | 0.40 | 97.54 | 98.55 | 121.73 | 122.21 |
Non-current Liabilities (Other) |
3.61 | — | — | — | 2.72 | 88.56 | 101.94 | 112.92 | 125.18 | 131.18 |
Total non-current liabilities |
3.61 | — | — | 2.60 | 4.21 | 88.95 | 201.06 | 212.31 | 248.57 | 259.51 |
Total liabilities |
6.75 | 7.04 | 13.47 | 22.09 | 25.65 | 111.33 | 224.98 | 243.52 | 294.51 | 305.93 |
Additional Paid In Capital |
43.50 | 115.69 | 212.92 | 407.99 | 452.53 | 475.70 | 487.79 | 614.04 | 797.25 | 854.09 |
Preferred Stock (Total) |
0.01 | — | — | — | — | — | — | — | — | — |
Common Stock (Net) |
0.01 | 0.04 | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | 0.09 | 0.12 | 0.13 |
Retained Earnings |
(27.21) | (47.21) | (122.87) | (228.02) | (356.50) | (467.32) | (577.10) | (679.35) | (806.22) | (959.72) |
Common Equity (Total) |
16.29 | 68.52 | 90.09 | 180.30 | 96.36 | 8.41 | (89.36) | (65.21) | (8.80) | (105.47) |
Shareholders Equity (Total) |
16.31 | 68.52 | 90.09 | 180.30 | 96.36 | 8.41 | (89.36) | (65.21) | (8.80) | (105.47) |
Shareholders Equity and Liabilities (Total) |
23.06 | 75.55 | 103.56 | 202.39 | 122.01 | 119.75 | 135.62 | 178.31 | 285.71 | 200.46 |
Shares (Common) |
2.31 | 13.75 | 16.22 | 21.03 | 22.17 | 22.46 | 23.13 | 32.49 | 42.23 | 48.35 |
Shares (Preferred) |
5.19 | — | — | — | — | — | — | — | — | — |
Shareholders Equity (Tangible) |
16.31 | 68.52 | 90.09 | 180.30 | 96.36 | 8.41 | (89.36) | (65.21) | (8.80) | (105.47) |
Net Debt |
(21.46) | (73.20) | (101.57) | (145.00) | (101.75) | (89.97) | (3.24) | (39.24) | (116.03) | 0.40 |
Total Debt |
— | — | — | 2.60 | 1.50 | 0.40 | 97.54 | 98.55 | 121.73 | 122.21 |